Grants for Special district governments - Federal

The Office of Refugee Resettlement (ORR), within the Administration for Children and Families (ACF), announces the availability of funds for the National Refugee Leadership and Lived Experience Council (NRLLEC) Program. The NRLLEC is a new program funded by the Office of Refugee Resettlement (ORR) that designs, implements, evaluates, and promotes national-level councils consisting of refugees and other ORR-eligible populations who have resettled into communities throughout the United States within the last five years. The NRLLEC Program will facilitate a National Young Adult Leadership Council comprised of members ages 18 to 24 every year for three years, as well as two additional councils with thematic focus to be determined in consultation with ORR. The NRLLEC Program will design, implement, evaluate, and promote five councils during the three-year project period. The programs primary goal is to positively impact the lives of council members and their refugee and larger communities by building council members capacity to serve as leaders. In addition, ORR recognizes that its engagement with these groups will enhance its ability to gather information from individual members firsthand about their lived experiences integrating into the United States. This will help inform ORR and its recipient network about how to best meet refugee needs through enhancing or changing ORR guidance, programming, and future councils. The NRLLEC Program will foster inclusivity, with council members attuned to the diversity, demographics, needs, and viewpoints of ORRs eligible population (https://www.acf.hhs.gov/orr/programs/refugees/factsheets). The NRLLEC Program will not seek consensus advice from council members.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.

This funding opportunity supports researchers in developing innovative tools to measure human behavior and synchronize these measurements with brain activity, aiming to advance our understanding of brain-behavior relationships and improve interventions for neurobehavioral conditions.

This funding opportunity is designed to support citizen science projects that enhance federal fisheries stock assessments and improve understanding of climate change impacts on fish stocks and fishing communities.

The "WaterSMART Drought Response Program: Drought Resiliency Projects for Fiscal Year 2025" grant is designed to provide financial assistance for the development and implementation of comprehensive drought plans and projects that enhance long-term resilience to drought, with a focus on benefiting disadvantaged communities and promoting collaboration among various stakeholders to address water management issues.

This funding opportunity supports researchers in analyzing existing oral health data or developing new statistical methods to improve data analysis, with a focus on establishing causal relationships rather than just identifying correlations.

The "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD" grant aims to fund innovative research strategies that use advanced tools to target and manipulate specific brain cells affected by aging, Alzheimer's Disease, and related dementias, in order to better understand these conditions and their impact on brain function.

This funding opportunity supports innovative research on how communication between mitochondria and the nucleus affects Alzheimer’s Disease and related dementias, inviting applications from universities, nonprofits, and other organizations.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UM2 activity code. Details of the planned NOFO are provided below.

This funding opportunity supports U.S.-based institutions in planning and implementing clinical trials aimed at improving treatments for dental, oral, and craniofacial conditions.

The "Type 1 Diabetes TrialNet Clinical Network Hub" grant aims to support the coordination unit for clinical trials focused on preventing and intervening early in type 1 diabetes, by improving communication, outreach, and developing new strategies for better screening, recruitment, and retention of participants.

This program provides funding to state and local governments, tribal authorities, and public agencies to enhance transportation infrastructure through innovative financing and public-private partnerships.

This funding opportunity provides financial support to organizations developing or expanding programs that help reduce reoffending among female juvenile delinquents by addressing their unique needs through direct intervention services.

This funding opportunity supports organizations in developing career development and mentoring programs for early-career researchers from diverse backgrounds who are underrepresented in the biomedical and behavioral sciences.

This funding opportunity supports research using human-derived ex vivo models to explore how HIV interacts with addictive substances, focusing on their effects on the brain and immune system.

This funding opportunity supports research on how inflammasome activation affects neurocognitive disorders and immune function in individuals with HIV and substance use disorders, encouraging studies that explore the interactions between these factors.